



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

MAINTENANCE OF CERTIFICATION EXAMINATION IN ADDICTION PSYCHIATRY

2020 Content Blueprint

(September 10, 2019)

| Number of questions: 150 | | |
|---------------------------------|--|-------------|
| 01. | Scientific foundations of addiction psychiatry | 9–11% |
| 02. | Evaluation | 23–27% |
| 03. | Treatment | 55–65% |
| 04. | Systems-based practice | 4–6% |
| TOTAL | | 100% |

Note: A more detailed content outline is shown below.



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

MAINTENANCE OF CERTIFICATION EXAMINATION IN ADDICTION PSYCHIATRY 2020 Content Outline

| |
|---|
| 01. Scientific foundations of addiction psychiatry |
| A. Epidemiology |
| B. Genetics |
| C. Behavior |
| D. Pharmacology |
| 1. Alcohol |
| 2. Sedatives, hypnotics, anxiolytics |
| 3. Cocaine and stimulants |
| 4. Opioids |
| 5. Cannabinoids |
| 6. Tobacco/nicotine |
| 7. PCP, hallucinogens, and inhalants |
| 8. Caffeine |
| 9. Other |
| E. Neurobiology |
| F. Other |
| 02. Evaluation |
| A. Screening |
| B. Comprehensive assessment and diagnosis |
| 1. DSM diagnostic criteria |
| 2. Signs and symptoms of intoxication and withdrawal |
| a. Alcohol |
| b. Sedatives, hypnotics, anxiolytics |
| c. Cocaine and stimulants |
| d. Opioids |
| e. Cannabinoids |
| f. Tobacco/nicotine |
| g. PCP, hallucinogens, and inhalants |
| h. Caffeine |
| i. Other |
| 3. Comorbidity |
| a. Psychiatric |
| b. Medical |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 4. Other |
| C. Laboratory testing |
| D. Psychometric testing |
| 03. Treatment |
| A. Pharmacotherapy |
| 1. Management of intoxication (toxicity) and withdrawal |
| a. Alcohol |
| b. Sedatives, hypnotics, anxiolytics |
| c. Cocaine and stimulants |
| d. Opioids |
| e. Cannabinoids |
| f. Tobacco/nicotine |
| g. PCP, hallucinogens, and inhalants |
| h. Other |
| 2. Relapse prevention |
| a. Alcohol |
| b. Opioids |
| c. Tobacco/nicotine |
| d. Other |
| 3. Management of co-occurring conditions |
| a. Psychiatric |
| b. Medical (including pain, HIV) |
| B. Psychotherapy and psychosocial treatment |
| 1. Brief intervention |
| 2. Motivational enhancement |
| 3. Cognitive behavior therapy |
| 4. Twelve-step facilitation |
| 5. Behavioral/contingency management |
| 6. Couples, family, and network therapies |
| 7. Mutual help approaches |
| 8. Other |
| C. Other |
| 04. Systems-based practice |
| A. Special populations |
| 1. Children and adolescents |
| 2. Geriatric |
| 3. Women (including pregnancy issues) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| | |
|----|--|
| 4. | Professionals (e.g., health care workers, athletes, pilots) |
| 5. | Ethnic and cultural groups |
| 6. | Gay and lesbian |
| 7. | Homeless |
| 8. | Forensics/incarcerated patients |
| 9. | Other |
| B. | Legal issues (e.g., laws, regulations) |
| C. | Public health and prevention, and public policy |
| D. | Health services |
| E. | Ethics and professionalism (e.g., privacy and confidentiality) |